Avicena Completes Dosing Phase of Parkinson's Study
Posted on: Tuesday, 6 February 2007, 09:00 CST
Avicena has completed the dose-escalating portion of a chronic toxicology study of its lead Parkinson's disease drug candidate.
Results, which demonstrated that the drug PD-02 is safe and well-tolerated, will allow Avicena to proceed with patient enrollment in a phase III Parkinson's disease study.
The FDA approved a phase III study design for PD-02 in April 2006, and requested a dose-escalating chronic toxicology study prior to patient enrollment. This study is designed to evaluate PD-02's potential to slow the progression of Parkinson's disease.
In preclinical studies, PD-02 has demonstrated significant neuroprotective properties including protection of the dopaminergic cells which are affected in Parkinson's disease.
Source: Datamonitor
Related Articles
- Gene Therapy Study For Parkinson's Disease
- Henry Ford West Bloomfield Hospital Launches Gene Therapy Study for Parkinson's Disease
- Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinson's Disease
- Brain stimulation studied for Parkinson's
- BrainStorm Cell Therapeutics NTF Cells Shows Significant Advantage in Pre-Clinical Study for Parkinson's Disease
- NeuroSearch Initiates Phase I Study of Parkinson's Disease
- BrainStorm Cell Therapeutics on the Road to Clinical Studies in Parkinson's Disease
- Avicena Completes Dose-Escalation Portion of Chronic Toxicology Study of Parkinson's Disease Drug Candidate PD-02
- Researcher Pioneered Studies into Parkinson's Disease That Remain Benchmarks
- Study Links Parkinson's Drug to Gambling
 |
 |
User Comments (0)
RSS Feeds